⌕
Acadia Pharmaceuticals · ACAD · Nasdaq
Tenet 65 · Solid
Compare
$18.32−1.87%At closeTenet 65 · Solid
$18.32−0.35 (−1.87%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Acadia Pharmaceuticals (ACAD) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (65 new · 148 increased · 89 reduced · 59 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 352 filers, Sep 30, 2026
# 13F FUNDS
352
13F VALUE
$3.5B
172.7M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 30, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERDisposed · Open-market sale3,321$20.88↗
Oct 15, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAcquired · Grant / award6,815—↗
Aug 6, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAcquired · Option exercise14,292$17.84↗
Aug 6, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERDisposed · Open-market sale5,000$29.00↗
Aug 6, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERDisposed · Open-market sale9,292$29.34↗
Aug 6, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERDisposed · Option exercise14,292Stock Option (Right to Buy)—↗
Aug 5, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAcquired · Option exercise5,849$17.84↗
Aug 5, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERDisposed · Open-market sale5,849$29.00↗
Aug 5, 2026Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERDisposed · Option exercise5,849Stock Option (Right to Buy)—↗
Jul 30, 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevDisposed · Open-market sale16,508$26.13↗
Jul 30, 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevDisposed · Open-market sale50$26.17↗
Jul 29, 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevAcquired · Option exercise32,272—↗
Jul 29, 2026Thompson Elizabeth H.Z.EVP, Head of Research & DevDisposed · Option exercise32,272Restricted Stock Units—↗
Jun 26, 2026Kihara JamesPRINCIPAL ACCOUNTING OFFICERDisposed · Open-market sale11,421$26.08↗
May 29, 2026BAKER BROS. ADVISORS LPdirectorAcquired · Grant / award18,622—↗
May 29, 2026BAKER BROS. ADVISORS LPdirectorAcquired · Grant / award18,622—↗
May 29, 2026BAKER BROS. ADVISORS LPdirectorAcquired · Grant / award32,008Non- Qualified Stock Option (right to buy)—↗
May 29, 2026BAKER BROS. ADVISORS LPdirectorAcquired · Grant / award32,008Non- Qualified Stock Option (right to buy)—↗
May 29, 2026Ndu AdoradirectorAcquired · Option exercise8,107—↗
May 29, 2026Ndu AdoradirectorDisposed · Option exercise8,107Restricted Stock Units—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Acadia Pharmaceuticals?

Acadia Pharmaceuticals was held by 352 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.